Statin Prevents Tissue Factor Expression in Human Endothelial Cells: Role of Rho/Rho-Kinase and Akt Pathways

Background—Tissue factor plays a pivotal role in thrombus formation in acute coronary syndromes. However, the regulatory mechanisms underlying tissue factor expression are poorly understood. Statins are effective in patients with acute coronary syndromes. Hence, the aim of this study was to clarify in human endothelial cells the signaling pathways of thrombin-induced tissue factor expression and potential inhibitory effects of statins. Methods and Results—In human aortic endothelial cells, simvastatin prevented tissue factor induction by thrombin (4 U/mL) in a concentration-dependent manner. The increase in tissue factor activity on the cell surface was also blocked by simvastatin. Simvastatin also prevented the upregulation of tissue factor expression and activity in human aortic smooth muscle cells. Mevalonate (100 &mgr;mol/L) reversed the inhibitory effect of simvastatin on tissue factor expression. Thrombin induced rapid activation of Rho A and p38 MAP kinase. The Rho-kinase inhibitor Y-27632 and the p38 MAP kinase inhibitor SB203580 prevented tissue factor induction. Akt was dephosphorylated by thrombin; the phosphoinositol 3-kinase inhibitor wortmannin enhanced its dephosphorylation as well as thrombin-induced tissue factor expression. Simvastatin prevented thrombin-induced Rho A activation but not p38 MAP kinase activation. Akt dephosphorylation by thrombin was blocked by both simvastatin and Y-27632. Conclusions—Endothelial tissue factor induction by thrombin is regulated by Rho/Rho-kinase, Akt, and p38 MAP kinase. Simvastatin prevents its induction through inhibition of Rho/Rho-kinase and activation of Akt. These findings provide new insights into the action of statins in acute coronary syndromes.

[1]  David Hunt,et al.  Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study , 2000, The Lancet.

[2]  D R Illingworth,et al.  The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. , 1997, The American journal of cardiology.

[3]  P. Libby,et al.  CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. , 2000, The American journal of pathology.

[4]  J. Fallon,et al.  In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[5]  P. Libby,et al.  An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.

[6]  P. Libby,et al.  Inflammation and thrombosis: the clot thickens. , 2001, Circulation.

[7]  B. Buckley,et al.  Statins do more than just lower cholesterol , 1996, The Lancet.

[8]  E. Tremoli,et al.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[9]  W. Aird,et al.  Vascular-bed--specific hemostasis and hypercoagulable states. , 1999, The New England journal of medicine.

[10]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[11]  J. Freyssinet,et al.  Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. , 1991, The Biochemical journal.

[12]  S. Coughlin,et al.  Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. , 1999, The Journal of clinical investigation.

[13]  SusannaColli,et al.  Vastatins Inhibit Tissue Factor in Cultured Human Macrophages , 1997 .

[14]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[15]  U. Laufs,et al.  Targeting Rho in cardiovascular disease. , 2000, Circulation research.

[16]  Kathleen M. Smith,et al.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Kaikita,et al.  Co‐localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis , 1999, The Journal of pathology.